Merck & Co., Inc. Increase (Decrease) in Accrued Liabilities
Merck & Co., Inc. (MRK) reported Increase (Decrease) in Accrued Liabilities of -$1.84 billion for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-02-24
- Merck & Co., Inc. increase (decrease) in accrued liabilities for fiscal 2025 was -$1.84B.
- Merck & Co., Inc. increase (decrease) in accrued liabilities for fiscal 2024 was -$2.33B, a 230.57% decline from fiscal 2023.
- Merck & Co., Inc. increase (decrease) in accrued liabilities for fiscal 2023 was $1.78B.
- Merck & Co., Inc. increase (decrease) in accrued liabilities for fiscal 2022 was -$50.00M, a 118.05% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities 12 month | Increase (Decrease) in Accrued Liabilities 12 month as first filed |
|---|---|---|
| 2025-12-31 | -$1.84B 10-K · filed 2026-02-24 | |
| 2024-12-31 | -$2.33B 10-K · filed 2026-02-24 | |
| 2023-12-31 | $1.78B 10-K · filed 2026-02-24 | |
| 2022-12-31 | -$50.00M 10-K · filed 2025-02-25 | |
| 2021-12-31 | $277.00M 10-K · filed 2024-02-26 | |
| 2020-12-31 | -$1.15B 10-K · filed 2023-02-24 | -$1.14B 10-K · filed 2021-02-25 |
| 2019-12-31 | $413.00M 10-K · filed 2022-02-25 | $376.00M 10-K · filed 2020-02-26 |
| 2018-12-31 | -$341.00M 10-K · filed 2021-02-25 | |
| 2017-12-31 | -$922.00M 10-K · filed 2020-02-26 | |
| 2016-12-31 | -$2.02B 10-K · filed 2019-02-27 | |
| 2015-12-31 | -$8.00M 10-K · filed 2018-02-27 | |
| 2014-12-31 | $1.64B 10-K · filed 2017-02-28 | |
| 2013-12-31 | -$397.00M 10-K · filed 2016-02-26 | |
| 2012-12-31 | -$717.00M 10-K · filed 2015-02-27 | |
| 2011-12-31 | $1.44B 10-K · filed 2014-02-27 | |
| 2010-12-31 | $35.00M 10-K · filed 2013-02-28 | |
| 2009-12-31 | -$4.00B 10-K · filed 2012-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |